^
Association details:
| Biomarker: | STRN-NTRK2 fusion + CDKN2B Deletion |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Durable Clinical Response to Larotrectinib in an Adolescent Patient With an Undifferentiated Sarcoma Harboring an STRN-NTRK2 Fusion
Excerpt:
...11-year-old female presented with...NRSTS, likely hemangiopericytoma, which upon review at our institution was revised to undifferentiated sarcoma....Sequencing revealed a novel STRN-NTRK2 fusion...Copy number loss of CDKN2B also was identified...response continues to deepen with complete resolution of her pulmonary metastasis and only residual PET-negative tissue at the site of tumor invasion of the vertebral bodies after 22 months of larotrectinib therapy...
DOI:
10.1200/PO.18.00101
Trial ID:
